Literature DB >> 9893664

The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups.

M D'Incalci1, M Bonfanti, A Pifferi, E Mascellani, G Tagliabue, D Berger, H H Fiebig.   

Abstract

Twenty-three human xenografts, including five colon, five gastric, nine lung (three small cell lung cancer) and four breast carcinomas, were investigated for their sensitivity to nitrosoureas, dacarbazine (DTIC), cyclophosphamide (CTX) and cisplatin (DDP). In 12 cases, at least one of the drugs produced complete or partial remission, in 2, a minor regression was observed and in the other 9, treatment was ineffective. The level of sensitivity to each drug, using a score from 1 to 5, was correlated to three biochemical parameters reported to be involved in resistance to alkylating agents: glutathione (GSH), glutathione transferase (GST) and O6-alkylguanine-DNA-alkyltransferase (AGT). A wide variability was found in these parameters in the xenografts investigated. No correlation was found between any of the three parameters and sensitivity to the drugs used or between sensitivity to one drug and to any of the other drugs tested. These results illustrate the complexity of the question of resistance to alkylating agents and indicate that, at least in xenografts, the biochemical parameters examined are not predictive of response to alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9893664     DOI: 10.1016/s0959-8049(98)00191-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

2.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 3.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

4.  Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards.

Authors:  Rachel Loeber; Erin Michaelson; Qingming Fang; Colin Campbell; Anthony E Pegg; Natalia Tretyakova
Journal:  Chem Res Toxicol       Date:  2008-02-14       Impact factor: 3.739

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

6.  A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer.

Authors:  Y Watanabe; M Koi; H Hemmi; H Hoshai; K Noda
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

Review 7.  DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.

Authors:  Ida Casorelli; Cecilia Bossa; Margherita Bignami
Journal:  Int J Environ Res Public Health       Date:  2012-07-27       Impact factor: 3.390

8.  Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours.

Authors:  M J Clemons; M C Bibby; H El Teraifi; G Forster; J Kelly; S Banerjee; B Cadman; W D J Ryder; A Howell; G P Margison
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

9.  O6-methylguanine-DNA methyltransferase as a prognostic and predictive marker for basal-like breast cancer treated with cyclophosphamide-based chemotherapy.

Authors:  Sayuri Isono; Makoto Fujishima; Tatsuya Azumi; Yukihiko Hashimoto; Yoshifumi Komoike; Masao Yukawa; Masahiro Watatani
Journal:  Oncol Lett       Date:  2014-03-20       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.